<DOC>
	<DOCNO>NCT00439283</DOCNO>
	<brief_summary>Continuous treatment anti-tumor necrosis factor alpha monoclonal antibody infliximab efficacious ankylose spondylitis ( AS ) , whereas treatment discontinuation result disease relapse , variable delay . Objective study compare efficacy continuous treatment infliximab , treatment adapt symptom recurrence . Addition methotrexate ( MTX ) infliximab also test .</brief_summary>
	<brief_title>Study Two Schedules Infliximab Maintenance Therapy Ankylosing Spondylitis</brief_title>
	<detailed_description>Patients active AS randomly assign receive infliximab every 6 week ( Q6 ) , upon symptom recurrence ( on-demand ) , follow load regimen infusion week 0 , 2 , 6 . Patients latter group randomly assign receive MTX , start 4 week prior infliximab . Monitoring perform one year . The primary end point proportion patient 20 % improvement response accord ASsessment Ankylosing Spondylitis ( ASAS ) criterion , week 54 .</detailed_description>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Adult patient ( &gt; 18 year old ) With diagnosis AS With least one follow evidence active inflammation , present within 3 month inclusion : serum Creactive protein ( CRP ) level twice upper limit value normal range , positive magnetic resonance image spine sacroiliac joint , vascularize enthesitis powerDoppler ultrasound technic . Presence clinically active axial disease , define 1 ) Bath AS Disease Activity Index ( BASDAI ) ( 18 ) ≥ 3/10 , 2 ) score ≥ 3/10 axial pain ( second item BASDAI ) . Diseasemodifying antirheumatic drug ( DMARDs ) , sulphasalazine , methotrexate , hydroxychloroquine , intramuscular gold , thiol compound , cyclosporin , intravenous biphosphonate discontinue least 4 week inclusion . Dosages NSAIDs corticosteroid require remain stable least 4 week inclusion . A negative pregnancy test result require non menopausal female patient , contraception study period six month last infusion infliximab recommend patient childbearing potential . Pregnancy . Breastfeeding . Vaccination live organism last month . Present infection episode serious infection within last three month . Active malignancy within previous five year . Alcohol drug addiction . Severe chronic concomitant disease . Administration investigational drug within last three month , know TNF inhibitor therapy past ( thalidomide , infliximab etanercept ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>Ankylosing spondylitis</keyword>
	<keyword>infliximab</keyword>
	<keyword>Systematic regimen</keyword>
	<keyword>On-demand regimen</keyword>
</DOC>